| 三氧化二砷新剂型的研究进展 |
| |
| 引用本文： | 廖润锐, 石春鹏, 付文琪, 沈秀芸, 支凤楠, 蒋雅楠. 三氧化二砷新剂型的研究进展[J]. 中国现代应用药学, 2023, 40(3): 414-420. DOI: 10.13748/j.cnki.issn1007-7693.2023.03.022 |
| |
| 作者姓名： | 廖润锐 石春鹏 付文琪 沈秀芸 支凤楠 蒋雅楠 |
| |
| 作者单位： | 哈尔滨医科大学药学院药理学教研室, 黑龙江省生物医药工程重点实验室-省部共建国家重点实验室培育基地, 心血管药物研究教育部重点实验室, 哈尔滨 150081;哈尔滨医科大学药学院药理学教研室, 黑龙江省生物医药工程重点实验室-省部共建国家重点实验室培育基地, 心血管药物研究教育部重点实验室, 哈尔滨 150081;黑龙江省医学科学院, 北方转化医学研究合作中心, 哈尔滨 150081 |
| |
| 基金项目： | 国家自然科学基金项目(81803524)；黑龙江省自然科学基金项目(LH2021H018)；中国博士后基金(2018M641878)；黑龙江省博士后科学基金(LBH-Z18168，LBH-Q21134)；哈尔滨医科大学药学院青年人才启动基金(2019-QD-02) |
| |
| 摘 要： | 三氧化二砷是急性早幼粒细胞白血病的一线用药，对多种实体瘤也具有抑制作用。然而，三氧化二砷肾脏清除速率快，无组织特异性分布，靶向性较差，易产生心、肝和肾等毒性作用，限制了其在实体瘤的临床应用。近年来，科学家开发大量三氧化二砷新剂型以提高其疗效，降低其不良反应，包括脂质体、微球、纳米粒、乳剂和悬浮剂等。本文对三氧化二砷的新剂型研究进展进行梳理，以期为三氧化二砷新剂型的合理开发和应用提供新思路。
|
| 关 键 词： | 三氧化二砷 新剂型 脂质体 纳米砷 |
| 收稿时间： | 2022-01-04 |
Research Progress of New Dosage Forms of Arsenic Trioxide |
| |
| LIAO Runrui, SHI Chunpeng, FU Wenqi, SHEN Xiuyun, ZHI Fengnan, JIANG Yanan. Research Progress of New Dosage Forms of Arsenic Trioxide[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(3): 414-420. DOI: 10.13748/j.cnki.issn1007-7693.2023.03.022 |
| |
| Authors: | LIAO Runrui SHI Chunpeng FU Wenqi SHEN Xiuyun ZHI Fengnan JIANG Yanan |
| |
| Affiliation: | Department of Pharmacology, College of Pharmacy, Harbin Medical University, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education, Harbin 150081, China; Department of Pharmacology, College of Pharmacy, Harbin Medical University, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education, Harbin 150081, China;Heilongjiang Academy of Medical Sciences, Translational Medicine Research and Cooperation Center of Northern China, Harbin 150081, China |
| |
| Abstract: | Arsenic trioxide is a first-line therapeutic drug for acute promyelocytic leukemia, has inhibitory effects on various solid tumor. However, arsenic trioxide has rapid renal clearance rate, without specific tissue distribution, poorly targeted and easy to produce adverse drug reactions including heart, liver, and kidney toxicity, which limited its clinical application in solid tumors. In recent years, plenty of new arsenic trioxide dosage forms have been continuously developed by scientists to improve its efficacy and reduce its adverse reaction, including liposomes, microspheres, nanoparticles, emulsions, suspension, etc. This review summarized the progresses in new dosage forms of arsenic trioxide, in order to provide new insights for the rational development and application of new arsenic trioxide dosage forms. |
| |
| Keywords: | arsenic trioxide new dosage forms liposomes nano arsenic |
|
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 |
|
点击此处可从《中国现代应用药学》下载全文 |
|
